title: Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia.
abstract: BACKGROUND
  An increased number of melanocytic nevi at the termination of chemotherapy has been documented in children with hematologic malignancies. The persistence of the increased number of nevi over time and the relationship with personal (e.g. phenotype) and disease related variables remain to be explored.
  
  
  METHODS
  One hundred Italian patients diagnosed as having acute lymphatic or myeloid leukemia, after 1975, were recruited and compared with a group of 100 control individuals drawn from friend of the enrolled patients. Information regarding lifetime sun exposure, phenotypic characteristics, and number of nevi was collected by experienced dermatologists. Counts of nevi were expressed both as totals and as counts per unit of body surface area ("density"). Multiple linear regression analysis was employed to control for potentially confounding factors when comparing patients and controls.
  
  
  RESULTS
  The patients and controls were fairly comparable in terms of constitutional characteristics, but the patients had a significantly higher number and density of nevi > or = 2 mm or larger in diameter. In addition, patients had a greater number of large nevi ( > or = 6 mm in greatest dimension), and of nevi in unusual areas, such as the palms and soles. Differences in nevus density between patients and controls were notably maintained in the older age group ( > 12 years). None of the disease-related factors analyzed (e.g. treatment protocol and radiotherapy), appeared to be significantly correlated with nevus density.
  
  
  CONCLUSIONS
  Patients with a history of childhood leukemia have a sustained increase in their nevus density. A fairly convincing body of evidence indicates that a large number of melanocytic nevi is the strongest risk factor for melanoma. Therefore, the utility of periodic skin examination of these should be considered.
authors.affiliation: Department of Dermatology, University of Milan, Bergamo General Hospital, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Naldi
authors.forename: L
authors.initials: L
authors.lastname: Adamoli
authors.forename: D
authors.initials: D
authors.lastname: Fraschini
authors.forename: A
authors.initials: A
authors.lastname: Corbetta
authors.forename: L
authors.initials: L
authors.lastname: Imberti
authors.forename: A
authors.initials: A
authors.lastname: Reseghetti
authors.forename: A
authors.initials: A
authors.lastname: Reciputo
authors.forename: E
authors.initials: E
authors.lastname: Rossi
authors.forename: T
authors.initials: T
authors.lastname: Cainelli
authors.forename: G
authors.initials: G
authors.lastname: Masera
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000150:complications* / Q000473:pathology; D008297:Male; D009508:Nevus, Pigmented / Q000209:etiology* / Q000473:pathology; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000473:pathology